Salvat plans to launch the first global ocular corticosteroid with nanoemulsion in 2023 for the inflammation and pain after ocular surgery
Phase III clinical trials conducted in US confirm that clobetasol is effective and safe in the treatment of inflammation and pain after cataract surgery. The pharmaceutical company has begun the process with health authorities to market the new corticosteroid worldwide by the middle of next year. The company has patented a pioneering technology, IMPACT-SVT®, which […]